CSL Ltd (ASX:CSL) Why Tariff Noise Does Not Change the Buy Thesis
CSL has pulled back meaningfully from its highs, and the latest round of tariff headlines has only added to the pressure. But when we dig into the actual exposure, the picture looks far more manageable than the market seems to be pricing in. We maintain a Buy rating on CSL with a price target of A$187.20, representing 34.9% upside from the current price of A$138.93. We think the sell-off is an opportunity, not a warning sign.
The headline risk around tariffs is real, but the substance behind it tells a different story. The vast majority of CSL’s product portfolio is either exempt from new tariff measures or only marginally affected. The estimated NPAT impact sits at just 1-2% for FY27 before mitigation, and there are clear pathways to offset even that modest drag. For a company of CSL’s quality and scale, this is noise rather than signal.
Research published 8 April 2026. Price target and upside based on prices at time of publication.
About CSL
CSL is a global biotechnology leader headquartered in Melbourne, Australia. The company operates across three main divisions. CSL Behring is the core plasma-derived therapies business, manufacturing immunoglobulins, albumin, clotting factors and specialty products used to treat serious and rare conditions including immune deficiencies, bleeding disorders and hereditary angioedema. Seqirus is one of the largest influenza vaccine companies globally, producing seasonal and pandemic influenza vaccines out of its manufacturing base in the United Kingdom. Vifor, acquired in 2022, focuses on iron deficiency, nephrology and cardio-renal therapies, giving CSL a meaningful presence in the renal care space. The company has a market capitalisation of approximately A$67.1 billion and sells into more than 100 countries worldwide.
Tariff Exposure in Context
The new US tariff regime that takes effect on 29 September 2026 has understandably generated concern across the healthcare sector, and CSL has not been immune to the sentiment. But the actual exposure is narrower than the broad headlines suggest. We have gone through the portfolio line by line, and the conclusion is that only a small portion of CSL’s revenue base faces any tariff headwind at all.
The products directly exposed are Mircera and Velphoro, both manufactured at CSL’s Swiss facilities. These fall under a 15% tariff on Swiss imports into the United States. The gross revenue impact from tariffs on these two products is estimated at US$89 million, but after adjusting for minority interest the net impact to CSL comes down to approximately US$48.9 million. That is a manageable number for a business generating over US$15 billion in annual revenue.
What matters just as much is what is not affected. The key immunoglobulin therapies, which form the backbone of CSL Behring’s earnings, are exempt from the tariff regime. The haemophilia product suite and the hereditary angioedema (HAE) treatments are also exempt. These are the products that drive the bulk of CSL’s US revenue, and they remain untouched.
The Seqirus and Influenza Angle
There was a separate question around Seqirus, specifically whether the UK-manufactured Fluad and broader influenza vaccine portfolio could be caught up in tariff measures. We expect these products to be exempt under the US-UK trade deal, which provides a carve-out for pharmaceutical and vaccine imports. Influenza vaccines more broadly are also expected to be exempt from the tariff regime regardless of origin.
This is significant because Seqirus has been a genuine growth engine for CSL in recent years. The business has scaled meaningfully, and any tariff hit to vaccine revenue would have been a real problem. The fact that it sits outside the affected perimeter is a material positive for the investment case.
What Gets Hit and What Does Not
To summarise the exposure cleanly, the tariff impact is concentrated in two Swiss-manufactured products (Mircera and Velphoro) and nothing else of real consequence. The exempt list is far longer and far more important to CSL’s earnings. IG therapies, haemophilia treatments, HAE products, influenza vaccines, and Seqirus broadly are all outside the tariff perimeter. The 1-2% hit to FY27 NPAT that we estimate is the pre-mitigation number, and even that assumes no management response at all.
Mitigation Pathways Are Available
CSL is not sitting idle on this. The company has several mitigation strategies available to offset the tariff headwind, and We expect management to actively pursue them. These include supply chain adjustments, pricing strategies and potential manufacturing reallocation over time. CSL has the scale, the global manufacturing footprint and the operational capability to manage around a tariff burden of this size. We would expect the actual bottom-line impact to be well below the gross headline number once mitigation is factored in.
This is a company that has navigated far more complex operational challenges, from pandemic-era plasma collection disruptions to the integration of Vifor, and come through in strong shape. A 15% tariff on two products out of a portfolio of dozens is not the kind of challenge that changes the trajectory of the business.
Financial Outlook Remains Solid
The financial profile heading into FY26 and FY27 continues to look strong. We estimate FY26 revenue at US$15,921 million, with EBITDA of US$5,242 million and earnings per share of US$6.80. These are not the numbers of a business under stress. CSL continues to grow its top line, expand margins as Vifor synergies flow through, and generate substantial free cash flow.
The plasma collection environment has normalised after the COVID disruption years, and CSL Behring is seeing steady volume growth across its key IG and specialty products. Seqirus continues to take share in the influenza vaccine market, and the Vifor integration has been delivering ahead of expectations on the cost synergy front. The tariff issue, in this context, is a minor friction on an otherwise clean earnings trajectory.
Valuation and the Opportunity
At A$138.93, CSL is trading at a meaningful discount to our price target of A$187.20 implies 34.9% upside. The stock has been caught up in broader market weakness and sector-wide tariff fears, but the company-specific fundamentals do not justify the current discount. CSL has the kind of earnings visibility, competitive moat and long-duration growth profile that typically commands a premium multiple, and the current price does not reflect that.
We think the risk-reward here is skewed firmly to the upside. The tariff headwind is quantified, modest, and manageable. The growth drivers across all three divisions remain intact. And the valuation is offering an entry point that we have not seen in some time for a business of this calibre.
Risks to Consider
The obvious near-term risk is further escalation of the tariff regime, either through higher rates or broader product coverage. If Swiss tariffs were to increase meaningfully beyond 15%, the Mircera and Velphoro impact would scale accordingly. There is also the possibility that future trade negotiations could bring UK pharmaceutical imports into scope, which would affect Seqirus more directly.
Beyond tariffs, the standard CSL risks apply. Plasma collection volumes remain sensitive to donor economics and competition for donors. Currency movements, particularly AUD/USD, can swing reported earnings materially. Regulatory risk around pricing and reimbursement in the US healthcare system is always present. And the Vifor integration, while tracking well, still has execution risk as synergy targets are pursued over the coming years.
None of these risks are new, and none of them change the structural thesis on CSL as a long-duration compounder in the global biotech space.
Our View
CSL remains one of the highest-quality businesses on the ASX, and the current pullback driven by tariff fears looks overdone relative to the actual exposure. The 1-2% NPAT impact in FY27 is a rounding error for a company with this growth profile, and even that modest hit is likely to be partially or fully offset by management action. The exempt status of CSL’s most important product lines, including all IG therapies, haemophilia treatments, HAE products and the entire Seqirus vaccine portfolio, means the earnings engine is fundamentally unaffected.
Our Buy rating and A$187.20 price target reflect a view that the market is mispricing the tariff risk, and we agree. For investors with a 12-month view, CSL at these levels looks like a compelling opportunity to own a world-class business at a discount that the fundamentals do not support.
If you would like to discuss CSL or any of our current research in more detail, feel free to get in touch with our team.
